Search Result

Results for "

insulinotropic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Dipeptidyl Peptidase (4) Free Fatty Acid Receptor (1) GCGR (9) GLP Receptor (4) Insulin Receptor (13) Peptide-Drug Conjugates (PDCs) (1) Potassium Channel (10) Reactive Oxygen Species (1)
By Research Areas:	Endocrinology (3) Metabolic Disease (39)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-B0682A

Mitiglinide calcium hydrate KAD-1229; S-21403	Potassium Channel	Metabolic Disease
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-17398

Mitiglinide calcium KAD-1229 anhydrous; S21403 anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-146455

DPP-4-IN-3	Dipeptidyl Peptidase Reactive Oxygen Species	Metabolic Disease
DPP-4-IN-3 (Compound 5a) is a potent dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 0.75 nM. DPP-4-IN-3 shows excellent antioxidant and insulinotropic activity .

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-B0682

Mitiglinide KAD-1229 free acid anhydrous; S21403 free acid anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-12413A

BMS-986118	Free Fatty Acid Receptor	Metabolic Disease
BMS-986118 is a potent, orally active, and selective GPR40 agonist with an EC₅₀ of 0.07 µM. BMS-986118 has dual insulinotropic and GLP-1 secretory effects, resulting in robust plasma glucose lowering effects in acute animal models .

HY-P2080C

GIP (1-30)-Myr	Insulin Receptor	Metabolic Disease
GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-103545

GIP (1-39) Gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-N6858

4-Hydroxyisoleucine 4-Hydroxy-L-isoleucine	Others	Metabolic Disease
4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties .

HY-B0682AR

Mitiglinide (calcium hydrate) (Standard)	Potassium Channel	Metabolic Disease
Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-N6858R

4-Hydroxyisoleucine (Standard)	Others	Metabolic Disease
4-Hydroxyisoleucine (Standard) is the analytical standard of 4-Hydroxyisoleucine. This product is intended for research and analytical applications. 4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties .

HY-P3506

Retatrutide 2 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 2 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .

HY-P3580A

Acetyl Gastric Inhibitory Peptide (human) (TFA) Human N-acetyl GIP TFA	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .

HY-P0055

GLP-1(7-37) Maximum Cited Publications 6 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0055A

GLP-1(7-37) acetate Maximum Cited Publications 6 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism .

HY-P2542

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .

HY-126198A

Linogliride fumarate McN-3935 fumarate	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) fumarate is an antidiabetic agent. Linogliride fumarate (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

HY-126198

Linogliride McN-3935	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) is an antidiabetic agent. Linogliride (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-B0422S

Nateglinide-d5 A4166 d₅; Senaglinide d₅	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-B0422R

Nateglinide (Standard) A4166 (Standard); Senaglinide (Standard)	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide (Standard) is the analytical standard of Nateglinide. This product is intended for research and analytical applications. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-B0682S2

Mitiglinide-d5 calcium	Potassium Channel	Metabolic Disease
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S1

(2R)-Mitiglinide-d5 calcium	Potassium Channel	Metabolic Disease
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S

Mitiglinide-d8 calcium hydrate	Potassium Channel	Metabolic Disease
Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-129658

TT-OAD2 free base	GCGR	Metabolic Disease
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 free base has the potential for diabetes treatment .

HY-129658A

TT-OAD2	GCGR	Metabolic Disease
TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment .

HY-P10138

human GIP(3-30) , amide	Insulin Receptor	Metabolic Disease
human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro .

HY-P10138A

human GIP(3-30), amide TFA	Insulin Receptor	Metabolic Disease
human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro .

Cat. No.	Product Name	Target	Research Area

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P3506

Retatrutide 2 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 2 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P2080C

GIP (1-30)-Myr	Insulin Receptor	Metabolic Disease
GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-103545

GIP (1-39) Gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon receptor (GCGR), glucosedependent insulinotropic* polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .

HY-P3580A

Acetyl Gastric Inhibitory Peptide (human) (TFA) Human N-acetyl GIP TFA	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .

HY-P0055

GLP-1(7-37) Maximum Cited Publications 6 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0055A

GLP-1(7-37) acetate Maximum Cited Publications 6 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism .

HY-P2542

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P10138

human GIP(3-30) , amide	Insulin Receptor	Metabolic Disease
human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro .

HY-P10138A

human GIP(3-30), amide TFA	Insulin Receptor	Metabolic Disease
human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6858

4-Hydroxyisoleucine 4-Hydroxy-L-isoleucine	Structural Classification other families Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Trigonella foenum-graecum Linn. Disease Research Fields	Others
4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties .

HY-N6858R

4-Hydroxyisoleucine (Standard)	Structural Classification other families Leguminosae Ketones, Aldehydes, Acids Source classification Plants Trigonella foenum-graecum Linn.	Others
4-Hydroxyisoleucine (Standard) is the analytical standard of 4-Hydroxyisoleucine. This product is intended for research and analytical applications. 4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties .

Species:	Human (2) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	His (5)
Source:	HEK293 (3) E. coli Cell-free (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702285

	GIPR Protein, Human (Cell-Free, His) Gastric inhibitory polypeptide receptor; Glucose-dependent insulinotropic polypeptide receptor	Human	E. coli Cell-free
	GIPR protein, a receptor for glucose-dependent insulinotropic polypeptide (GIP), operates through G proteins that activate adenylyl cyclase. Its capacity for homodimer and heterodimer formation with GLP1R implies potential interactions between receptors linked to incretin hormones. GIPR Protein, Human (Cell-Free, His) is the recombinant human-derived GIPR protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of GIPR Protein, Human (Cell-Free, His) is 445 a.a., with molecular weight of 52.4 kDa.

HY-P702800

	GIPR Protein, Human (HEK293, His) Gastric inhibitory polypeptide receptor; Glucose-dependent insulinotropic polypeptide receptor	Human	HEK293
	GIPR protein, a receptor for glucose-dependent insulinotropic polypeptide (GIP), operates through G proteins that activate adenylyl cyclase. Its capacity for homodimer and heterodimer formation with GLP1R implies potential interactions between receptors linked to incretin hormones. GIPR Protein, Human (HEK293, His) is the recombinant human-derived GIPR, expressed by HEK293 , with C-10*His labeled tag. The total length of GIPR Protein, Human (HEK293, His) is 117 a.a..

HY-P702801

	GIPR Protein, Mouse (HEK293, His) Gastric inhibitory polypeptide receptor; Glucose-dependent insulinotropic polypeptide receptor	Mouse	HEK293
	GIPR protein, a receptor for glucose-dependent insulinotropic polypeptide (GIP), operates through G proteins that activate adenylyl cyclase. Its capacity for homodimer and heterodimer formation with GLP1R implies potential interactions between receptors linked to incretin hormones. GIPR Protein, Mouse (HEK293, His) is the recombinant human-derived GIPR, expressed by HEK293 , with C-10*His labeled tag.

HY-P702803

	GIPR Protein, Cynomolgus (P.pastoris, His) Gastric inhibitory polypeptide receptor; Glucose-dependent insulinotropic polypeptide receptor	Cynomolgus	P. pastoris
	GIPR Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived GIPR, expressed by P. pastoris , with N-6*His labeled tag. The total length of GIPR Protein, Cynomolgus (P.pastoris, His) is 113 a.a.,

HY-P702802

	GIPR Protein, Rat (HEK293, His) Gastric inhibitory polypeptide receptor; Glucose-dependent insulinotropic polypeptide receptor	Rat	HEK293

Compare Products

Products

Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample
Size

Cat. No.	Product Name	Chemical Structure

HY-B0422S

Nateglinide-d5
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-B0682S2

Mitiglinide-d5 calcium
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S1

(2R)-Mitiglinide-d5 calcium
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S

Mitiglinide-d8 calcium hydrate

Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

insulinotropic

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products